MORPHOLOGICAL EVALUATION OF THE EFFECTIVENESS OF HYDROSURGICAL SYSTEM VERSAJET® IN CONJUNCTION WITH COMBINED ANTIBIOTIC THERAPY IN THE TREATMENT OF NECROTIC COMPLICATIONS OF DIABETIC FOOT SYNDROME WITH BIOFILM FORMS OF BACTERIA

Objective – to study the dynamics of reparative processes in the purulonecrotic wound in cases of diabetic foot syndrome. The subjects treated in this study included three groups of patients: Group 1 – after surgical treatment of wounds and topical treatment with ointments on polyethylene glycol basis; Group 2 – after surgical treatment of wounds with hydrosurgical system VersaJet® and intravenous systemic antibiotics therapy, chosen according to the results antibiogram; Group 3 – after surgical treatment of wounds with hydrosurgical system VersaJet® and combination systemic antibiotic therapy (a drug selected as a result of antibiogram plus clarithromycin). There is shown the ultrastructure of a microbial biofilm, the effect of antimicrobial agents on its destruction and the structural and functional state of microbial populations and injury cells. The high efficiency of the hydrosurgery system VersaJet® and combined systemic antibiotic therapy with clarithromycin in the treatment regimen, and dressings with ointments on PEG basis for the treatment of purulonecrotic wounds in patients with neuropathic form of diabetic foot syndrome. Already on the 5th day of the complex wound treatment the morphological study of the biopsy materials of the wounds showed no presence of biofilms on the surface of the wound, and in its deepest layers. Free (plankton-like) cells of microorganisms were also none. Effective purification of wounds from microbial and cellular detritus was indicated that led to the intensification of the functional and proliferative activity of the cells of the granulation tissue. Such dynamics of wound process in almost all Group 3 patients allowed to conduct the final stage of treatment (plastic reconstruction of the foot) in a shorter time. Introduced for the Group 3 of patients the algorithm of complex treatment prevents the formation of new microbial biofilms, increases the activity of systemic antimicrobials even in the identification of multiple-antibiotic resistant strains.

1. Галстян Г.Р., Дедов И.И. Организация помощи больным с синдромом диабетической стопы в Российской Федерации. Сахарный диабет 2009;(1):4–7. [Galstyan G.R., Dedov I.I. Organization of the aid to diabetic foot syndrome patients in the Russian Federation. Sakharnyy diabet = Diabetes Mellitus 2009;(1):4–7. (In Russ.)].

2. Дедов И.И. Сахарный диабет: развитие технологий в диагностике, лечении и профилактике (пленарная лекция). Сахарный диабет 2010;(3):6–13. [Dedov I.I. Diabetes mellitus: Development of diagnostic, treatment and preventive technologies (plenary lection). Sakharnyy diabet = Diabetes Mellitus 2010;(3):6–13. (In Russ.)].

3. Митиш В.А., Пасхалова Ю.С., Махкамова Ф.Т. Оценка средней стоимости комплексного хирургического лечения нейроишемической формы синдрома диабетической стопы в рамках оказания высокотехнологичной медицинской помощи. В сб.: Материалы I Международного конгресса «Раны и раневые инфекции». М., 2012. С. 241–2. [Mitish V.A., Paskhalova Yu.S., Makhkamova F.T. Estimation of the average cost of complex surgical treatment of neuro-ischemic form of diabetic foot syndrome in the provision of high-tech medical care. In: Proceedings of the 1st International Congress “The wounds and wound infections”. Мoscow, 2012. Pp. 241–2. (In Russ.)].

4. Светухин А.М., Земляной А.Б., Колтунов В.А. Особенности комплексного хирургического лечения нейропатической формы синдрома диабетической стопы. Инфекции в хирургии 2008;6(1):64–7. [Svetukhin A.M., Zemlyanoy A.B., Koltunov V.A. Features of the complex surgical treatment of neuropathic form of diabetic foot syndrome. Infektsii v khirurgii = Infections in Surgery 2008;6(1):64–7. (In Russ.)].

5. Ryder M.A. Catheter-related Infections: It’s all about biofilm. Topics in Advanced Practice Nursing eJournal 2005;5(3).

6. Olson M., Ceri H., Morck D.W. et al. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res 2002;66(2):86–92.

7. Афиногенова А.Г., Даровская Е.Н. Микробные биопленки ран: состояние вопроса. Травматология и ортопедия России 2011;3(61):119–25. [Afinogenova A.G., Darovskaya E.N. Microbial biofilm of injuries: state of the question. Travmatologiya i ortopedia Rossii = Russian Traumatology and Orthopedics 2011;3(61):119–25. (In Russ.)].

8. Гостев В.В., Сидоренко С.В. Бактериальные биопленки и инфекции. Журнал инфектологии 2010;2(3):4–15. [Gostev V.V., Sidorenko S.V. Bacterial biofilm formation and infections. Zhurnal infektologii = Infectology Journal 2010;2(3):4–15. (In Russ.)].

9. Costerton J.W., Geesey G.G., Cheng K.J. How bacteria stick. Sci Am 1978;238(1):86–95.

10. Costerton J.W., Cheng K.J., Geesey G.G. et al. Bacterial biofilms in nature and disease. Annu Rev Microbiol 1987;41:435–64.

11. del Pozo J.L., Patel R. The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther 2007;82(2):204–9.

12. Donlan R.M. Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. Clin Infect Dis 2011;52(8):1038–45.

13. James G.A., Swogger E., Wolcott R. et al. Biofilms in chronic wounds. Wound Repair Regen 2008;16(1):37–44.

14. Bester E., Kroukamp O., Wolfaardt G.M. et al. Metabolic differentiation in biofilms as indicated by carbon dioxide production rates. Appl Environ Microbiol 2010;76(4):1189–97.

15. Белобородова Н.В., Байрамов И.Т. Роль микробных сообществ или биопленок в кардиохирургии. Антибиотики и химиотерапия 2008;53(11–12):44–59.[Beloborodova N.V., Bairamov I.T. The role of microbial communities or biofilms in cardiac surgery. Antibiotiki i khimioterapiya = Antibiotics and Chemotherapy 2008;53(11–12):44–59. (In Russ.)].

16. Зубков М.Н. Внебольничные пневмонии: роль макролидов возрастает. Русский медицинский журнал 2006;14(21):1545–51. [Zubkov M.N. Community-acquired pneumonia: the role of macrolides is increasing. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2006;14(21):1545–51. (In Russ.)].

17. Толордава Э.Р., Перепанова Т.С., Егамбердиев Д.К., Романова Ю.М. Изучение процесса образования биопленки патогенными микроорганизмами на поверхности почечных камней. Клиническая лабораторная диагностика 2010;(9):31–2. [Tolordava E.R., Perepanova T.S., Egamberdiev D.K., Romanova Yu.M. Studying the process of biofilm formation by pathogenic microorganisms on the surface of kidney-stones. Klinicheskaya laboratornaya diagnostika = Clinical Laboratory Diagnostics 2010;(9):31–2. (In Russ.)].

18. Ильина Т.С., Романова Ю.М., Гинцбург А.Л. Биопленки как способ существования бактерий в окружающей среде и организме хозяина: феномен, генетический контроль и системы регуляции их развития. Генетика 2004;40(11):1–12. [Ilyina T.S., Romanova Yu.M., Gintsburg A.L. Biofilms as a way of existence of bacteria in the environment and the host organism: the phenomenon, genetic control and regulation systems for their development. Genetika = Genetics 2004;40:1–12. (In Russ.)].

19. Доронина Л.П., Митиш В.А., Галстян Г.Р. Использование гидрохирургической системы VersaJet у больных с синдромом диабетической стопы. Сахарный диабет 2010;(3):121–6. [Doronina L.P., Mitish V.A., Galstyan G.R. Usage of hydrosurgical system VersaJet® in diabetic foot patients’ treatment. Sakharnyy diabet = Diabetes mellitus 2010;(3):121–6. (In Russ.)].

20. Kaplan J.B. Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. J Dent Res 2010;89(3):205–18.

21. Шуб Г.М., Швиденко И.Г., Пронина Е.А., Белобородова Н.В. Материалы к элективному курсу «Микробные сообщества». Саратовский научно-медицинский журнал 2010;6(2):245–7. [Shub G.M., Shvidenko I.G., Pronina E.A., Beloborodova N.V. Materials for the elective courses “Microbial community”. Saratovskiy nauchno-meditsinskiy zhurnal = Saratov Scientific-Medical Journal 2010;6(2):245–7. (In Russ.)].

22. Wozniak D.J., Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004;125(2 Suppl):625–95.

23. Sano M., Hirose T., Nishimura M. et al. Inhibitory action of clarithromycin on glycocalyx produced by MRSA. J Infect Chemother 1999;5(1):10–5.

24. Walters M.C. 3rd, Roe F., Bugnicourt A. еt al. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003;47(1):317–23.